<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16937</article-id><article-id pub-id-type="doi">10.15789/2220-7619-AOT-16937</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Assessment of trec and krec levels in COVID-19 patients with varying disease severity</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка уровней молекул trec и krec у больных COVID-19 с разной степенью тяжести течения заболевания</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7603-3269</contrib-id><name-alternatives><name xml:lang="en"><surname>Saitgalina</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Сайтгалина</surname><given-names>Мария Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Molecular Immunology</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории молекулярной иммунологии </p></bio><email>Sajgalinam@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2270-8897</contrib-id><name-alternatives><name xml:lang="en"><surname>Ostankova</surname><given-names>Yulia V.</given-names></name><name xml:lang="ru"><surname>Останкова</surname><given-names>Юлия Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Head of the Laboratory of HIV Immunology and Virology; Senior Researcher, Laboratory of Molecular Immunology</p></bio><bio xml:lang="ru"><p>к.б.н., зав. лабораторией иммунологии и вирусологии ВИЧ-инфекции; старший научный сотрудник лаборатории молекулярной иммунологии </p></bio><email>shenna1@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2490-308X</contrib-id><name-alternatives><name xml:lang="en"><surname>Arsentieva</surname><given-names>Natalia A.</given-names></name><name xml:lang="ru"><surname>Арсентьева</surname><given-names>Наталья Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Senior Researcher, Laboratory of Molecular Immunology</p></bio><bio xml:lang="ru"><p>к.б.н., старший научный сотрудник лаборатории молекулярной иммунологии </p></bio><email>arsentieva_n.a@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0535-5014</contrib-id><name-alternatives><name xml:lang="en"><surname>Korobova</surname><given-names>Zoya R.</given-names></name><name xml:lang="ru"><surname>Коробова</surname><given-names>Зоя Романовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Molecular Immunology</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории молекулярной иммунологии </p></bio><email>zoia-korobova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-7092-6773</contrib-id><name-alternatives><name xml:lang="en"><surname>Liubimova</surname><given-names>Natalia E.</given-names></name><name xml:lang="ru"><surname>Любимова</surname><given-names>Наталья Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Researcher, Laboratory of Molecular Immunology</p></bio><bio xml:lang="ru"><p>к.б.н., научный сотрудник лаборатории молекулярной иммунологии </p></bio><email>natelu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8822-9165</contrib-id><name-alternatives><name xml:lang="en"><surname>Kashchenko</surname><given-names>Victor A.</given-names></name><name xml:lang="ru"><surname>Кащенко</surname><given-names>Виктор Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Professor, Deputy-Director for Scientific and Educational Work; Head of the Department of Faculty Surgery</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зам. генерального директора по научно-образовательной работе ; зав. кафедрой факультетской хирургии </p></bio><email>surg122@yandex.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kulikov</surname><given-names>Alexandr N.</given-names></name><name xml:lang="ru"><surname>Куликов</surname><given-names>Александр Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Professor, Head of the Department of Propaedeutics of Internal Diseases</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой пропедевтики внутренних болезней</p></bio><email>ankulikov2005@yandex.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pevtsov</surname><given-names>Dmitry E.</given-names></name><name xml:lang="ru"><surname>Певцов</surname><given-names>Дмитрий Эдуардович</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD (Medicine), Transfusiologist, Head of the Blood Transfusion Department, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation</p></bio><bio xml:lang="ru"><p>к.м.н., руководитель отделения переливания крови, врач-трансфузиолог НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой </p></bio><email>dmitriipevtcov@gmail.com</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6894-6121</contrib-id><name-alternatives><name xml:lang="en"><surname>Stanevich</surname><given-names>Oksana V.</given-names></name><name xml:lang="ru"><surname>Станевич</surname><given-names>Оксана Владимировна</given-names></name></name-alternatives><bio xml:lang="en"><p>Infectious Disease Physician, Department of Epidemiology of Clinics</p></bio><bio xml:lang="ru"><p>врач-инфекционист отдела эпидемиологии клиник</p></bio><email>oksana.stanevich@gmail.com</email><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chernykh</surname><given-names>Ekaterina I.</given-names></name><name xml:lang="ru"><surname>Черных</surname><given-names>Екатерина Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Admitting Physician</p></bio><bio xml:lang="ru"><p>д.м.н., врач-терапевт приемного отделения </p></bio><email>ekaterina_cherny@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4571-8799</contrib-id><name-alternatives><name xml:lang="en"><surname>Totolian</surname><given-names>Areg A.</given-names></name><name xml:lang="ru"><surname>Тотолян</surname><given-names>Арег Артемович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>RAS Full Member, PhD, MD (Medicine), Professor, Director; Head of the Department of Immunology</p></bio><bio xml:lang="ru"><p>академик РАН, д.м.н., профессор, директор; зав. кафедрой иммунологии </p></bio><email>totolian@pasteurorg.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">St. Petersburg Pasteur Institute</institution></aff><aff><institution xml:lang="ru">ФБУН НИИ эпидемиологии и микробиологии имени Пастера</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">North-Western District Scientific and Clinical Center named after L.G. Sokolov Federal Medical and Biological Agency</institution></aff><aff><institution xml:lang="ru">ФГБУ Северо-Западный окружной научно-клинический центр имени Л.Г. Соколова Федерального медико-биологического агентства</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">St. Petersburg State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Санкт-Петербургский государственный университет</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Министерства здравоохранения РФ</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Smorodintsev Research Institute of Influenza</institution></aff><aff><institution xml:lang="ru">ФГБУ НИИ гриппа им. А.А. Смородинцева Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-10-20" publication-format="electronic"><day>20</day><month>10</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-11-30" publication-format="electronic"><day>30</day><month>11</month><year>2023</year></pub-date><volume>13</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>873</fpage><lpage>884</lpage><history><date date-type="received" iso-8601-date="2023-10-05"><day>05</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-10-05"><day>05</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Saitgalina М.A., Ostankova Y.V., Arsentieva N.A., Korobova Z.R., Liubimova N.E., Kashchenko V.A., Kulikov A.N., Pevtsov D.E., Stanevich O.V., Chernykh E.I., Totolian A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Сайтгалина М.А., Останкова Ю.В., Арсентьева Н.А., Коробова З.Р., Любимова Н.Е., Кащенко В.А., Куликов А.Н., Певцов Д.Э., Станевич О.В., Черных Е.И., Тотолян А.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Saitgalina М.A., Ostankova Y.V., Arsentieva N.A., Korobova Z.R., Liubimova N.E., Kashchenko V.A., Kulikov A.N., Pevtsov D.E., Stanevich O.V., Chernykh E.I., Totolian A.A.</copyright-holder><copyright-holder xml:lang="ru">Сайтгалина М.А., Останкова Ю.В., Арсентьева Н.А., Коробова З.Р., Любимова Н.Е., Кащенко В.А., Куликов А.Н., Певцов Д.Э., Станевич О.В., Черных Е.И., Тотолян А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/16937">https://iimmun.ru/iimm/article/view/16937</self-uri><abstract xml:lang="en"><p>According to the WHO data, the number of infected people exceeded 765.2 million people during the COVID-19 pandemic. The severity of patient’s condition is determined by immune system hyperactivation. Activation of T- and B-lymphocyte subsets plays a prominent role in the control of infectious process. A content of small circular DNA molecules — T-cell receptor excision circles (TREC — T-cell receptor excision circles) and B-cell (“kappa”) excision rings (KREC — Kappa-deleting recombination excision circles) — in the peripheral blood can be used as a marker of the functionally active T and B cells maturation. The purpose of this work is to quantify peripheral blood TREC and KREC level in patients with the new coronavirus infection COVID-19 of varying severity. <italic>Materials and methods.</italic> The material consisted of 1028 blood samples from patients with a confirmed diagnosis of COVID-19, as well as 717 blood samples from apparently healthy volunteers. The content of TREC and KREC DNA fragments in the total DNA fraction was assessed by quantitative Real-time PCR using the “TREC/KREC-AMP PS” test system (St. Petersburg Pasteur Institute, Russia). Blood cell phenotyping was carried out using flow cytometry. <italic>Results.</italic> TREC/KREC levels were significantly reduced in COVID-19 patients (p &lt; 0.0001 at 95% CI). A significant direct correlation was established between the levels of peripheral blood TREC molecules and level of CD45<sup>+</sup>CD3<sup>+</sup>CD19<sup>–</sup> T cells (r = 0.59, p &lt; 0.0001), as well as between KREC level and count of CD45<sup>+</sup>CD3<sup>–</sup>CD19<sup>+</sup> B cells (r = 0.66, p &lt; 0.0001). The level of TREC molecules in patients with severe vs. moderate infection was significantly reduced in patients aged 30–39 years old (p = 0.0404) and 40–49 years old (p = 0.0356). The negative correlation between severity of COVID-19 clinical manifestations and TREC level in the blood of patients in 30–49 year age group indicates about an opportunity of using this analyte as a diagnostic and prognostic laboratory marker of patient’s condition. A simple PCR analysis algorithm makes it relevant to use the described method for assessing a state of immunity in coronavirus patients in the context of systemic negative impact of the SARS-CoV-2 virus on human organism.</p></abstract><trans-abstract xml:lang="ru"><p>По данным ВОЗ за период пандемии COVID-19 количество зараженных превысило 765,2 млн человек. Тяжесть состояния пациентов определяется гиперактивацией иммунной системы. Значимую роль в контроле инфекционного процесса играет активация субпопуляций T- и B-лимфоцитарных клеток. Одним из маркеров созревания функционально активных Т- и В-клеток может служить содержание в периферической крови небольших кольцевых молекул ДНК — Т-клеточных эксцизионных колец (TREC — T-cell receptor excision circles) и B-клеточных («каппа») эксцизионных колец (KREC — Kappa-deleting recombination excision circles) соответственно. Цель настоящей работы: дать количественную оценку содержания молекул TREC и KREC в периферической крови больных с новой коронавирусной инфекцией COVID-19 с разной степенью тяжести течения инфекционного процесса. <italic>Материалы и методы.</italic> Материалом служили 1028 образцов крови от пациентов с подтвержденным диагнозом COVID-19 со среднетяжелым, тяжелым или крайне тяжелым течением, а также 717 образцов крови от условно здоровых добровольцев. Оценку содержания ДНК-фрагментов TREC и KREC в тотальной фракции ДНК проводили методом количественной Real-time ПЦР с использованием тест-системы «TREC/KREC-AMP PS» (ФБУН НИИ Пастера, Россия). Для биообразцов, полученных от тяжелых и крайне тяжелых больных, проводили фенотипирование клеток крови методом проточной цитометрии. Статистическую обработку данных осуществляли с помощью программного обеспечения GraphPad Prizm 5 и Microsoft Exсel 2010. <italic>Результаты</italic>. Уровни TREC и/или KREC у больных COVID-19 достоверно снижены (p &lt; 0,0001 при 95% ДИ). Установлена достоверная прямая корреляционная зависимость уровней молекул TREC с количеством CD45<sup>+</sup>CD3<sup>+</sup>CD19<sup>–</sup> Т-клеток (r = 0,59, p &lt; 0,0001) и уровней молекул KREC c количеством СD45<sup>+</sup>CD3<sup>–</sup>CD19<sup>+</sup> В-клеток (r = 0,66, p &lt; 0,0001) в периферической крови. Уровень молекул TREC у больных с тяжелым течением инфекционного процесса достоверно снижен по сравнению с больными средней тяжести в группах пациентов 30–39 лет (p = 0,0404) и 40–49 лет (p = 0,0356). Отрицательная корреляционная зависимость между тяжестью клинических проявлений COVID-19 и уровнем TREC в крови больных в возрастном диапазоне 30–49 лет свидетельствует о возможности применения данного аналита как диагностического и прогностического лабораторного маркера состояния пациента. Несложный алгоритм ПЦР-анализа делает актуальным применение описанного способа оценки состояния иммунитета коронавирусных больных в условиях системного негативного влияния вируса SARS-CoV-2 на организм человека.</p></trans-abstract><kwd-group xml:lang="en"><kwd>TREC</kwd><kwd>KREC</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>immune status</kwd><kwd>laboratory markers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>TREC</kwd><kwd>KREC</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>иммунный статус</kwd><kwd>лабораторные маркеры</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Арсентьева Н.А., Любимова Н.Е., Бацунов О.К., Коробова З.Р., Станевич О.В., Лебедева А.А., Воробьев Е.А, Воробьева С.В., Куликов А.Н., Лиознов Д.А., Шарапова М.А., Певцов Д.Э., Тотолян А.А. Цитокины в плазме крови больных COVID-19 в острой фазе заболевания и фазе полного выздоровления // Медицинская иммунология. 2021. Т. 23, № 2. С. 311–326. [Arsentieva N.A., Liubimova N.E., Batsunov O.K., Korobova Z.R., Stanevich O.V., Lebedeva A.A., Vorobyov E.A., Vorobyova S.V., Kulikov A.N., Lioznov D.A., Sharapova M.A., Pevtcov D.E., Totolian A.A. Plasma cytokines in patients with COVID-19 during acute phase of the disease and following complete recovery. Meditsinskaya immunologiya = Medical Immunology (Russia), 2021, vol. 23, no. 2, pp. 311–326. (In Russ.)] doi: 10.15789/1563-0625-pci-2312</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Кудрявцев И.В., Головкин А.С., Тотолян Арег А. Т-хелперы и их клетки-мишени при COVID-19 // Инфекция и иммунитет. Т. 12, № 3. С. 409–426. [Kudryavtsev I.V., Golovkin A.S., Totolian Areg A. T helper cell subsets and related target cells in acute COVID-19. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2022, vol. 12, no. 3, pp. 409–426. (In Russ.)] doi: 10.15789/2220-7619-thc-1882022</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Сайтгалина М.А., Любимова Н.Е., Останкова Ю.В., Кузнецова Р.Н., Тотолян Арег А. Определение референтных интервалов циркулирующих в крови эксцизионных колец TREC и KREC у лиц старше 18 лет // Медицинская иммунология. 2022. Т. 24, № 6. С. 1227–1236. [Saitgalina M.A., Liubimova N.E., Ostankova Yu.V., Kuznetzova R.N., Totolian A.A. Determination of reference values for TREC and KREC in circulating blood of the persons over 18 years. Meditsinskaya immunologiya = Medical Immunology (Russia), 2022, vol. 24, no. 6, pp. 1227–1236. (In Russ.)] doi: 10.15789/1563-0625-dor-2587</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Сайтгалина М.А., Останкова Ю.В., Арсентьева Н.А., Коробова З.Р., Любимова Н.Е., Кащенко В.А., Куликов А.Н., Певцов Д.Э., Станевич О.В., Черных Е.И., Тотолян А.А. Значимость определения уровней молекул TREC и KREC в периферической крови для прогноза исхода заболевания COVID-19 в острый период // Российский иммунологический журнал. 2023, Т. 26, № 4. С. 611–618. [Saitgalina M.A., Ostankova Yu.V., Arsentieva N.A., Korobova Z.R., Lyubimova N.E., Kashchenko V.A., Kulikov A.N., Pevtsov D.E., Stanevich O.V., Chernykh E.I., Totolian A.A. Levels of TREC and KREC molecules significance determining in peripheral blood for predicting the outcome of COVID-19 disease in the acute period. Rossiiskii immunologicheskii zhurnal = Russian Journal of Immunology, 2023, vol. 26, no. 4, pp. 611–618. (In Russ.)] doi: 10.46235/1028-7221-14714-lot</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Сайтгалина М.А., Останкова Ю.В., Любимова Н.Е., Семенов А.В., Кузнецова Р.Н., Тотолян А.А. Модифицированный метод количественного определения уровней TREC и KREC в периферической крови у больных с иммунодефицитными состояниями // Инфекция и иммунитет. 2022. Т. 12, № 5. C. 981–996. [Saitgalina M.A., Ostankova Yu.V., Liubimova N.E., Semenov A.V., Kuznetsova R.N., Totolian A.A. Modified quantitative approach for assessing peripheral blood TREC and KREC levels in immunodeficient patients. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2022, vol. 12, no. 5, pp. 981–996. (In Russ.)] doi: 10.15789/2220-7619-mmf-2039</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Сайтгалина М.А., Останкова Ю.В., Седых А.В., Тотолян Арег А. Особенности преаналитического этапа при количественном определении TREC/KREC в периферической крови // Медицинская иммунология. 2023. Т. 25, № 6. С. 1441–1452. [Saitgalina M.A., Ostankova Yu.V., Sedykh A.V., Totolian Areg A. Features of the preanalytical stage in the quantitative determination of TREC/KREC in peripheral blood. Meditsinskaya immunologiya = Medical Immunology (Russia), 2023, vol. 25, no. 6, pp. 1441–1452. (In Russ)] doi: 10.15789/1563-0625-fot-2909</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Седых А.В., Сайтгалина М.А., Останкова Ю.В., Тотолян Арег А. Сравнительный анализ наборов реагентов для выделения ДНК из сухих пятен крови // Медицинская иммунология. 2023. Т. 25, № 6. С. 1453–1462. [Sedykh A.V., Saitgalina M.A., Ostankova Yu.V., Totolian Areg A. Comparative analysis of reagent kits for DNA extraction from dried blood spots. Meditsinskaya immunologiya = Medical Immunology (Russia), 2023, vol. 25, no. 6, pp. 1453–1462. (In Russ.)] doi: 10.15789/1563-0625-cao-2895</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bakin E.A., Stanevich O.V., Chmelevsky M.P., Belash V.A., Belash A.A., Savateeva G.A., Bokinova V.A., Arsentieva N.A., Sayenko L.F., Korobenkov E.A., Lioznov D.A., Totolian A.A., Polushin Yu.S., Kulikov A.N. A novel approach for COVID-19 patient condition tracking: from instant prediction to regular monitoring. Front. Med. (Lausanne), 2021, vol. 8: 744652. doi: 10.3389/fmed.2021.744652</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chen R., Yu Y., Li W., Liu Y., Lu J., Chen F., Zhou Q., Xia Zh., Gao L., Meng Q., Ma D. Gastrointestinal symptoms associated with unfavorable prognosis of COVID-19 patients: a retrospective study. Front. Med., 2020, vol. 7: 608259. doi: 10.3389/fmed.2020.608259</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cheung C.Y., Poon L.L., Ng I.H., Luk W., Sia S.F., Wu M.H., Chan K.H., Yuen K.Y., Gordon S., Guan Y., Peiris J.S. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol., 2005, vol. 79, no. 12, pp. 7819–7826. doi: 10.1128/jvi.79.12.7819-7826.2005</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of Coronavirus disease 2019 in China. N. Engl. J. Med., 2020, vol. 382, no. 18, pp. 1708–1720. doi: 10.1056/nejmoa2002032</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Guarneri C., Venanzi R.E., Gallizzi R., Ceccarelli M., Cannavò S.P., Nunnari G. Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19. J. Eur. Acad. Dermatol. Venereol., 2020, vol. 34, no. 9, pp. e449–e450. doi: 10.1111/jdv.16669</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev., 2020, vol. 53, pp. 13–24. doi: 10.1016/j.cytogfr.2020.05.009</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Habas K., Nganwuchu C., Shahzad F., Gopalan R., Haque M., Rahman S., Majumder A.A., Nasim T. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev. Anti. Infect. Ther., 2020, vol. 18, no. 12, pp. 1201–1211. doi: 10.1080/14787210.2020.1797487</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol., 2021, vol. 93, no. 1, pp. 250–256. doi: 10.1002/jmv.26232</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., W. Wu, Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jafarzadeh A., Jafarzadeh S., Nozari P., Mokhtari P., Nemati M. Lymphopenia an important immunological abnormality in patients with COVID-19: possible mechanisms. Scand. J. Immunol., 2021, vol. 93, no. 2: e12967. doi: 10.1111/sji.12967</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Korobova Z.R., Zueva E.V., Arsentieva N.A., Batsunov O.K., Liubimova N.E., Khamitova I.V., Kuznetsova R.N., Rubinstein A.A., Savin T.V., Stanevich O.V., Kulikov A.N., Pevtsov D.E., Totolian A.A. Changes in anti-SARS-CoV-2 IgG subclasses over time and in association with disease severity. Viruses, 2022, vol. 14, no. 5: 941. doi: 10.3390/v14050941</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kudryavtsev I.V., Arsentieva N.A., Batsunov O.K., Korobova Z.R., Khamitova I.V., Isakov D.V., Kuznetsova R.N., Rubinstein A.A., Stanevich O.V., Lebedeva A.A., Vorobyov E.A., Vorobyova S.V, Kulikov A.N., Sharapova M.A., Pevtcov D.E., Totolian A.A. Alterations in B cell and follicular T-helper cell subsets in patients with acute COVID-19 and COVID-19 convalescents. Curr. Issues Mol. Biol., 2022, vol. 44, no. 1, pp. 194–205. doi:10.3390/cimb44010014</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol., 2020, vol. 109, no. 5, pp. 531–538. doi: 10.1007/s00392-020-01626-9</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect., 2020, vol. 9, no. 1, pp. 727–732. doi: 10.1080/22221751.2020.1746199</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, vol. 395, no. 10229, pp. 1033–1034. doi: 10.1016/s0140-6736(20)30628-0</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol., 2020, vol. 20, no. 7, pp. 355–362. doi: 10.1038/s41577-020-0353-y</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Pascarella G., Strumia A., Piliego C., Bruno F., Del Buono R., Costa F., Scarlata S., Agrò F.E. COVID-19 diagnosis and management: a comprehensive review. J. Intern. Med., 2020, vol. 288, no. 2, pp. 192–206. doi: 10.1111/joim.13091</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ratajczak M.Z., Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. Leukemia, 2020, vol. 34, no. 7, pp. 1726–1729. doi: 10.1038/s41375-020-0887-9</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Savchenko A.A., Tikhonova E., Kudryavtsev I., Kudlay D., Korsunsky I., Beleniuk V., Borisov A. TREC/KREC levels and T and B lymphocyte subpopulations in COVID-19 patients at different stages of the disease. Viruses, 2022, vol. 14, no. 3: 646. doi: 10.3390/v14030646</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Serana F., Chiarini M., Zanotti C., Sottini A., Bertoli D., Bosio A., Caimi L., Imberti L. Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. J. Transl. Med., 2013, vol. 11: 119 doi: 10.1186/1479-5876-11-119</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Van Zelm M., Van der Burg M., Langerakand A., Van Dongen J. PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders. Front. Immunol., 2011, vol. 2: 12. doi: 10.3389/fimmu.2011.00012</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>WHO Coronavirus (COVID-19) Dashboard. URL: https://covid19.who.int (04.10.2023)</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Wong C.K., Lam C.W., Wu A.K., Ip W.K., Lee N.L., Chan I.H., Lit L.C., Hui D.S., Chan M.H., Chung S.S., Sung J.J. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol., 2004, vol. 136, no. 1, pp. 95–103. doi: 10.1111/j.1365-2249.2004.02415.x</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci., 2020, vol. 12, no. 1: 8. doi: 10.1038/s41368-020-0074-x</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., XiaP., Dong J., Zhao J., Wang F.-S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., 2020, vol. 8, no. 4, pp. 420–422. doi: 10.1016/S2213-2600(20)30076-X</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis., 2020, vol. 94, pp. 91–95. doi: 10.1016/j.ijid.2020.03.017</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Yuki K., Fujiogi M., Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin. Immunol., 2020, vol. 215: 108427. doi: 10.1016/j.clim.2020.108427</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, vol. 395, no. 10229, pp. 1054–1062. doi: 10.1016/S0140-6736(20)30566-3</mixed-citation></ref></ref-list></back></article>
